6 extractive question-and-answer pairs built from Standard Treatment Workflow on Paediatric Abdominal Tuberculosis, published by icmr.gov.in. Every answer is a verbatim span of text the source prints, and each row carries the passage it sits in, its offset in that passage, the source quote, the page and the location in the document, so any row can be checked against the original. 5 of the 6 pairs (83.3%) are explanatory questions and 1 restate a figure. 100.00% of rows pass the corpus quality gate.
Use the API URL with your free DD token in notebooks, scripts, and pipelines.
https://www.desidata.in/api/datasets/standard-treatment-workflow-on-paediatric-abdominal-tuberculosis-question-and/downloadDataset downloads are free. For Python or API downloads, sign in once and create a free DD token; set it as DD_TOKEN or save it in your notebook's secrets. Requests are linked to your account so your download history and counts stay accurate.
# One-time install: pip install desidata
# Set DD_TOKEN in your environment first (create a free token in Profile & settings).
import desidata
df = desidata.load("standard-treatment-workflow-on-paediatric-abdominal-tuberculosis-question-and")
df.head()Sign in with Google to download.
Usable for analysis, but expect some cleaning before you rely on it.
Consensus Document on Management of Pancreatic Cancer - Question and Answer Dataset
Economy · 268 rows
ICMR Standard Treatment Workflow for Cataract - Question and Answer Dataset
Economy · 27 rows
Neurology Questions from P a R T N E R S - Question and Answer Dataset
Economy · 107 rows
Beginner's Guide for Systematic Reviews - Question and Answer Dataset
Economy · 407 rows
Annual Report 2015-16 by agriwelfare.gov.in - Question and Answer Dataset
Economy · 1,013 rows
Higher Education in India - Question and Answer Dataset
Economy · 1,594 rows
Gender Policy of NABARD - Question and Answer Dataset
Economy · 14 rows
ICAR Annual Report 2025-26 - Question and Answer Dataset
Economy · 1,101 rows
First 6 of 6 rows
| question | answer | context | answer_start | question_type | knowledge_quality_score | source_quote | source_page | source_location | confidence | validation_status |
|---|---|---|---|---|---|---|---|---|---|---|
| What supportive treatments are suggested for managing malnutrition in abdominal conditions? | Management of SAM/Malnutrition as per national guidelines | SPLEEN, PANCREAS) • Abdominal pain, distension • Fever • Weight loss TREATMENT • Start treatment & follow-up as per NTEP • ATT for 6 months (2HRZE + 4HRE) • Pyridoxine supplementation- 10 mg/day • Steroids- Routinely not recommended (SAIO) • Supportive treatment- Management of SAM/Malnutrition as per national guidelines • Surgical treatment: › Acute intestinal obstruction, Bowel perforation › Persistence of obstructive symptoms despite conservative management & ATT | 264 | summary | 0.970 | SPLEEN, PANCREAS) • Abdominal pain, distension • Fever • Weight loss TREATMENT • Start treatment & follow-up as per NTEP • ATT for 6 months (2HRZE + 4HRE) • Pyridoxine supplementation- 10 mg/day • Steroids- Routinely not recommended (SAIO) • Supportive treatment- Management of SAM/Malnutrition as per national guidelines • Surgical treatment: › Acute intestinal obstruction, Bowel perforation › Persistence of obstructive symptoms despite conservative management & ATT | 1 | page=1,block=8 | 0.700 | valid |
| In what situations is surgical treatment advised for abdominal conditions? | Acute intestinal obstruction, Bowel perforation › Persistence of obstructive symptoms despite conservative management & ATT | SPLEEN, PANCREAS) • Abdominal pain, distension • Fever • Weight loss TREATMENT • Start treatment & follow-up as per NTEP • ATT for 6 months (2HRZE + 4HRE) • Pyridoxine supplementation- 10 mg/day • Steroids- Routinely not recommended (SAIO) • Supportive treatment- Management of SAM/Malnutrition as per national guidelines • Surgical treatment: › Acute intestinal obstruction, Bowel perforation › Persistence of obstructive symptoms despite conservative management & ATT | 346 | list | 0.820 | SPLEEN, PANCREAS) • Abdominal pain, distension • Fever • Weight loss TREATMENT • Start treatment & follow-up as per NTEP • ATT for 6 months (2HRZE + 4HRE) • Pyridoxine supplementation- 10 mg/day • Steroids- Routinely not recommended (SAIO) • Supportive treatment- Management of SAM/Malnutrition as per national guidelines • Surgical treatment: › Acute intestinal obstruction, Bowel perforation › Persistence of obstructive symptoms despite conservative management & ATT | 1 | page=1,block=8 | 0.700 | valid |
| What are the indicators for investigating DR TB? | Non response to treatment or Worsening or deterioration of constitutional symptoms after initial improvement. Rule out Crohn's disease OR Inflammatory Bowel Disease | • No response to appropriate treatment • Oral drug (ATT) intolerance/cannot be given MONITORING • Assessment of response to treatment: › Clinical follow up - every month during treatment & after that every 3 months › Radiologically by USG - At the end of treatment or if worsening or non response to treatment › Microbiological - If worsening or non response to treatment • Pointers towards DR TB investigation: › Non response to treatment or Worsening or deterioration of constitutional symptoms after initial improvement. Rule out Crohn's disease OR Inflammatory Bowel Disease • Obstructive symptoms may persist or worsen despite treatment with appropriate ATT • Monitor for › Adherence to treatment (ATT) › Adverse drug reactions- ATT induced | 414 | list | 0.820 | • No response to appropriate treatment • Oral drug (ATT) intolerance/cannot be given MONITORING • Assessment of response to treatment: › Clinical follow up - every month during treatment & after that every 3 months › Radiologically by USG - At the end of treatment or if worsening or non response to treatment › Microbiological - If worsening or non response to treatment • Pointers towards DR TB investigation: › Non response to treatment or Worsening or deterioration of constitutional symptoms after initial improvement. Rule out Crohn's disease OR Inflammatory Bowel Disease • Obstructive | ||||
| What aspects should be monitored during treatment with ATT? | Adherence to treatment (ATT) › Adverse drug reactions- ATT induced | • No response to appropriate treatment • Oral drug (ATT) intolerance/cannot be given MONITORING • Assessment of response to treatment: › Clinical follow up - every month during treatment & after that every 3 months › Radiologically by USG - At the end of treatment or if worsening or non response to treatment › Microbiological - If worsening or non response to treatment • Pointers towards DR TB investigation: › Non response to treatment or Worsening or deterioration of constitutional symptoms after initial improvement. Rule out Crohn's disease OR Inflammatory Bowel Disease • Obstructive symptoms may persist or worsen despite treatment with appropriate ATT • Monitor for › Adherence to treatment (ATT) › Adverse drug reactions- ATT induced | 679 | list | 0.820 | Rule out Crohn's disease OR Inflammatory Bowel Disease • Obstructive symptoms may persist or worsen despite treatment with appropriate ATT • Monitor for › Adherence to treatment (ATT) › Adverse drug reactions- ATT induced | 1 | page=1,block=16 | 0.700 | valid |
| What diagnostic procedures are optional for intestinal involvement in abdominal TB? | Ileocolonoscopy, tissue biopsy (HPE, NAAT) • Laparoscopy, tissue biopsy for HPE, NAAT | CLINICAL FEATURES SPECIFIC TO TYPE OF ABDOMINAL TB RED FLAGS • Pain abdomen waking child from sleep • Chronic, severe, or nocturnal diarrhea • Presence of constitutional symptoms like fever, anorexia, weight loss, etc. • Localized distension or mass ESSENTIAL • Ultrasound abdomen Ascites Essential • If exudative ascites, ascitic fluid for NAAT, TB culture • No role of ADA Enlarged Abdominal mass Desirable • USG guided Abdominal mass-FNA for cytology, NAAT, TB culture Optional • USG/CT guided core biopsy of LN for histology, NAAT, TB culture Intestinal involvement Desirable • CECT Abdomen/CT enterography • USG guided Abdominal Mass -FNA for cytology, NAAT, culture Optional • Ileocolonoscopy, tissue biopsy (HPE, NAAT) • Laparoscopy, tissue biopsy for HPE, NAAT | 683 | list | 0.820 | • Localized distension or mass ESSENTIAL • Ultrasound abdomen Ascites Essential • If exudative ascites, ascitic fluid for NAAT, TB culture • No role of ADA Enlarged Abdominal mass Desirable • USG guided Abdominal mass-FNA for cytology, NAAT, TB culture Optional • USG/CT guided core biopsy of LN for histology, NAAT, TB culture Intestinal involvement Desirable • CECT Abdomen/CT enterography • USG guided Abdominal Mass -FNA for cytology, NAAT, culture Optional • Ileocolonoscopy, tissue biopsy (HPE, NAAT) • Laparoscopy, tissue biopsy for HPE, NAAT | ||||
| How frequently should clinical follow-ups be conducted during and after treatment? | every month during treatment & after that every 3 months | • No response to appropriate treatment • Oral drug (ATT) intolerance/cannot be given MONITORING • Assessment of response to treatment: › Clinical follow up - every month during treatment & after that every 3 months › Radiologically by USG - At the end of treatment or if worsening or non response to treatment › Microbiological - If worsening or non response to treatment • Pointers towards DR TB investigation: › Non response to treatment or Worsening or deterioration of constitutional symptoms after initial improvement. Rule out Crohn's disease OR Inflammatory Bowel Disease • Obstructive symptoms may persist or worsen despite treatment with appropriate ATT • Monitor for › Adherence to treatment (ATT) › Adverse drug reactions- ATT induced | 158 | factual | 0.570 | • No response to appropriate treatment • Oral drug (ATT) intolerance/cannot be given MONITORING • Assessment of response to treatment: › Clinical follow up - every month during treatment & after that every 3 months › Radiologically by USG - At the end of treatment or if worsening or non response to treatment › Microbiological - If worsening or non response to treatment • Pointers towards DR TB investigation: › Non response to treatment or Worsening or deterioration of constitutional symptoms after initial improvement. |
Read straight from the file — download or use the API URL for the full dataset.
| 1 |
| page=1,block=16 |
| 0.700 |
| valid |
| 1 |
| page=1,block=27 |
| 0.700 |
| valid |
| 1 |
| page=1,block=16 |
| 0.700 |
| valid |